Departments of1Neurosurgery and.
2Internal Medicine.
J Neurosurg. 2018 Apr;128(4):1241-1249. doi: 10.3171/2016.12.JNS161967. Epub 2017 May 12.
OBJECTIVE Craniectomy is often performed to decrease intracranial pressure following trauma and vascular injuries. The subsequent cranioplasty procedures may be complicated by surgical site infections (SSIs) due to prior trauma, foreign implants, and multiple surgeries through a common incision. Several studies have found that intrawound vancomycin powder (VP) is associated with decreased risk of SSIs after spine operations. However, no previously published study has evaluated the effectiveness of VP in cranioplasty procedures. The purpose of this study was to determine whether intrawound VP is associated with decreased risk of SSIs, to evaluate VP's safety, and to identify risk factors for SSIs after cranioplasty among patients undergoing first-time cranioplasty. METHODS The authors conducted a retrospective cohort study of adult patients undergoing first-time cranioplasty for indications other than infections from January 1, 2008, to July 31, 2014, at an academic health center. Data on demographics, possible risk factors for SSIs, and treatment with VP were collected from the patients' electronic health records. RESULTS During the study period, 258 patients underwent first-time cranioplasties, and 15 (5.8%) of these patients acquired SSIs. Ninety-two patients (35.7%) received intrawound VP (VP group) and 166 (64.3%) did not (no-VP group). Patients in the VP group and the no-VP group were similar with respect to age, sex, smoking history, body mass index, and SSI rates (VP group 6.5%, no-VP group 5.4%, p = 0.72). Patients in the VP group were less likely than those in the no-VP group to have undergone craniectomy for tumors and were more likely to have an American Society of Anesthesiologists physical status score > 2. Intrawound VP was not associated with other postoperative complications. Risk factors for SSI from the bivariable analyses were diabetes (odds ratio [OR] 3.65, 95% CI 1.07-12.44), multiple craniotomy procedures before the cranioplasty (OR 4.39, 95% CI 1.47-13.18), prior same-side craniotomy (OR 4.73, 95% CI 1.57-14.24), and prosthetic implants (OR 4.51, 95% CI 1.40-14.59). The multivariable analysis identified prior same-side craniotomy (OR 3.37, 95% CI 1.06-10.79) and prosthetic implants (OR 3.93, 95% CI 1.15-13.40) as significant risk factors for SSIs. After adjusting for potential confounders, patients with SSIs were more likely than those without SSIs to be readmitted (OR 7.28, 95% CI 2.07-25.60). CONCLUSIONS In this study, intrawound VP was not associated with a decreased risk of SSIs or with an increased risk of complications. Prior same-side craniotomy and prosthetic implants were risk factors for SSI after first-time cranioplasty.
目的
开颅术常用于创伤和血管损伤后降低颅内压。
随后的颅骨修复术可能由于先前的创伤、外来植入物和通过同一切口进行的多次手术而导致手术部位感染(SSI)。
几项研究发现,在脊柱手术后,使用伤口内万古霉素粉(VP)可降低 SSI 的风险。
但是,以前没有发表的研究评估过 VP 在颅骨修复术中的有效性。
本研究旨在确定伤口内 VP 是否与降低颅骨修复术后 SSI 的风险相关,评估 VP 的安全性,并确定首次颅骨修复术后 SSI 的危险因素。
方法
作者对 2008 年 1 月 1 日至 2014 年 7 月 31 日在学术医疗中心接受颅骨修复术的非感染原因的成年患者进行了回顾性队列研究。
从患者的电子健康记录中收集了人口统计学数据、SSI 的可能危险因素以及 VP 治疗的数据。
结果
在研究期间,有 258 例患者接受了首次颅骨修复术,其中 15 例(5.8%)发生了 SSI。
92 例患者(35.7%)接受了伤口内 VP(VP 组),166 例(64.3%)未接受(无 VP 组)。
VP 组和无 VP 组在年龄、性别、吸烟史、体重指数和 SSI 发生率方面相似(VP 组 6.5%,无 VP 组 5.4%,p=0.72)。
VP 组患者行颅骨切除术治疗肿瘤的可能性小于无 VP 组,并且更可能具有美国麻醉医师协会身体状况评分>2。
伤口内 VP 与其他术后并发症无关。
单变量分析的 SSI 危险因素为糖尿病(比值比[OR]3.65,95%置信区间[CI]1.07-12.44)、颅骨修复术前多次开颅术(OR 4.39,95%CI 1.47-13.18)、同侧颅骨修复术史(OR 4.73,95%CI 1.57-14.24)和假体植入物(OR 4.51,95%CI 1.40-14.59)。
多变量分析确定同侧颅骨修复术史(OR 3.37,95%CI 1.06-10.79)和假体植入物(OR 3.93,95%CI 1.15-13.40)为 SSI 的显著危险因素。
调整潜在混杂因素后,与无 SSI 的患者相比,发生 SSI 的患者更有可能被再次入院(OR 7.28,95%CI 2.07-25.60)。
结论
在这项研究中,伤口内 VP 并未降低 SSI 的风险,也未增加并发症的风险。
同侧颅骨切开术和假体植入物是首次颅骨修复术后 SSI 的危险因素。